Clovis Crumbles On Data Disclosure, Possible FDA Delay
This article was originally published in Scrip
Executive Summary
Investors' hopes for an early approval of Clovis Oncology Inc.'s experimental lung cancer drug rociletinib were crushed on Nov. 16 after the company disclosed the drug's response rates were much lower than the firm had earlier reported.